These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 30345836)

  • 1. Biomarkers for Barrett's esophagus - a contemporary review.
    Qureshi AP; Stachler MD; Haque O; Odze RD
    Expert Rev Mol Diagn; 2018 Nov; 18(11):939-946. PubMed ID: 30345836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic and Epigenetic Alterations in Barrett's Esophagus and Esophageal Adenocarcinoma.
    Kaz AM; Grady WM; Stachler MD; Bass AJ
    Gastroenterol Clin North Am; 2015 Jun; 44(2):473-89. PubMed ID: 26021206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDX2, COX2 and MUC2 expressions in Barrett's esophagus: can they be useful in determination of the dysplasia?
    Türkmen IÇ; Başsüllü N; Uraz S; Yerdel MA; Memışoğlu R; Bülbül Doğusoy G
    Turk Patoloji Derg; 2012; 28(3):251-8. PubMed ID: 23011828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and Management of Low-Grade Dysplasia in Barrett's Esophagus: Expert Review From the Clinical Practice Updates Committee of the American Gastroenterological Association.
    Wani S; Rubenstein JH; Vieth M; Bergman J
    Gastroenterology; 2016 Nov; 151(5):822-835. PubMed ID: 27702561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CEACAM 6, a novel marker for the diagnosis of Barrett's esophagus.
    Sharma N; Srivastava S; Kern F; Xian W; Yeoh KG; Ming T; McKeon F; Ho KY
    Dis Esophagus; 2017 Jul; 30(7):1-5. PubMed ID: 28475729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of imaging and biomarkers in diagnosing Barrett's esophagus and predicting the risk of neoplastic progression.
    Ramzan Z; Nassri AB; Huerta S
    Expert Rev Mol Diagn; 2014 Jun; 14(5):575-91. PubMed ID: 24831686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular biomarkers and ablative therapies for Barrett's esophagus.
    Chisholm JA; Mayne GC; Hussey DJ; Watson DI
    Expert Rev Gastroenterol Hepatol; 2012 Sep; 6(5):567-81. PubMed ID: 23061708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diagnosis and management of Barrett's esophagus.
    DeMeester SR; DeMeester TR
    Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical use of p53 in Barrett's esophagus.
    Keswani RN; Noffsinger A; Waxman I; Bissonnette M
    Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1243-9. PubMed ID: 16835318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers in Barrett's Esophagus: Role in Diagnosis, Risk Stratification, and Prediction of Response to Therapy.
    Bansal A; Fitzgerald RC
    Gastroenterol Clin North Am; 2015 Jun; 44(2):373-90. PubMed ID: 26021200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarker identification and trans-regulatory network analyses in esophageal adenocarcinoma and Barrett's esophagus.
    Lv J; Guo L; Wang JH; Yan YZ; Zhang J; Wang YY; Yu Y; Huang YF; Zhao HP
    World J Gastroenterol; 2019 Jan; 25(2):233-244. PubMed ID: 30670912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression profile and cellular localizations of mucin proteins, CK7, and cytoplasmic p27 in Barrett's esophagus and esophageal adenocarcinoma.
    Ozcan HEA; Anuk T; Ozden O
    Adv Med Sci; 2018 Sep; 63(2):296-300. PubMed ID: 29803118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
    Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
    Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma.
    Bani-Hani K; Martin IG; Hardie LJ; Mapstone N; Briggs JA; Forman D; Wild CP
    J Natl Cancer Inst; 2000 Aug; 92(16):1316-21. PubMed ID: 10944553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Mutational Testing of Preneoplastic Barrett's Mucosa by Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Endoscopic Samples for Detection of Concurrent Dysplasia and Adenocarcinoma in Barrett's Esophagus.
    Del Portillo A; Lagana SM; Yao Y; Uehara T; Jhala N; Ganguly T; Nagy P; Gutierrez J; Luna A; Abrams J; Liu Y; Brand R; Sepulveda JL; Falk GW; Sepulveda AR
    J Mol Diagn; 2015 Jul; 17(4):412-9. PubMed ID: 26068095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.
    Anaparthy R; Gaddam S; Kanakadandi V; Alsop BR; Gupta N; Higbee AD; Wani SB; Singh M; Rastogi A; Bansal A; Cash BD; Young PE; Lieberman DA; Falk GW; Vargo JJ; Thota P; Sampliner RE; Sharma P
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1430-6. PubMed ID: 23707463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus.
    Villanacci V; Rossi E; Zambelli C; Galletti A; Cestari R; Missale G; Casa DD; Bassotti G
    Dig Liver Dis; 2007 Apr; 39(4):305-11. PubMed ID: 17307036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
    Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Esophageal adenocarcinoma arising in cervical inlet patch with synchronous Barrett's esophagus-related dysplasia.
    Tanaka M; Ushiku T; Ikemura M; Shibahara J; Seto Y; Fukayama M
    Pathol Int; 2014 Aug; 64(8):397-401. PubMed ID: 25143128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
    Rygiel AM; Milano F; Ten Kate FJ; Schaap A; Wang KK; Peppelenbosch MP; Bergman JJ; Krishnadath KK
    Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1380-5. PubMed ID: 18559552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.